Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy

Renal Failure

Volumn 32, Issue 2, 2010, Pages 172-178

  Roozbeh, Jamshid ^a   Banihashemi, Mohammad Amin ^b   Ghezlou, Mohammad ^a   Afshariani, Raha ^b   Salari, Soheila ^c   Moini, Maryam ^b   Sagheb, Mohammad Mahdi ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Captopril; Diabetic nephropathies; Pentoxifylline; Proteinuria; Randomized controlled trial

Indexed keywords

CAPTOPRIL; CREATININE; HEMOGLOBIN A1C; PENTOXIFYLLINE; PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERKALEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CHI-SQUARE DISTRIBUTION; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PROTEINURIA; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 77749279785     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003602645     Document Type: Article

References (29)

1. World Health Organization Burden of disease project. Available at http://www3.who.int/topics/global-burden-of-disease/en/ (accessed December 2008).
2. Atkins RC. The changing patterns of chronic kidney disease: The need to develop strategies for prevention relevant to different regions and countries. Kidney Int Suppl. 2005;68 (Suppl. 98):S83-S85.
3. Graves DT, Kayal RA. Diabetic complications and dysregu-lated innate immunity. Front Biosci. 2008;13:1227-1239.
4. Keane WF, Lyle PA. Reduction of endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Recent advances in management of type 2 diabetes and nephr-opathy: Lessons from the RENAAL study. Am J Kidney Dis. 2003;41 (Suppl. 1):S22-S25.
5. Zoja C, Benigni A, Remuzzi G. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol. 1999;7:420-428.
6. Navarro JF, Milena FJ, Mora C, et al. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pen-toxifylline administration. Am J Nephrol. 2006;26:562-570.
7. Ruggenenti P, Remuzzi G. The role of protein traffic in the progression of renal diseases. Annu Rev Med. 2000;51:315-327.
8. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997;51:2-15.
9. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
10. Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med. 1989;321:80-85.
11. Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991;40:1007-1012.
12. Navarro JF, Mora-Fernández C. The role of TNF-alpha in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 2006;17:441-450.
13. Rodriguez-Morán M, González-González G, Bermúdez-Barba MV, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3-10.
14. Solerte SB, Fioravanti M, Patti AL, et al. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol Lat. 1987;24:229-239.
15. Navarro JF, Mora C, Muros M, García J. Additive antipro-teinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16: 2119-2126.
16. Paap CM, Simpson KS, Horton MW, Schaefer KL, Lassman HB, Sack MR. Multiple-dose pharmacokinetics of pentoxi-fylline and its metabolites during renal insufficiency. Ann Pharmacother. 1996;30:724-729.
17. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345:910-912.
18. Hamilton RA, Kane MP, Demers J. Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis. Pharmacotherapy. 2003;23:909-915.
19. Berl T. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: The case for AT1 receptor antagonist. J Am Soc Nephrol. 2004; 15 (Suppl. 1):S71-S76.
20. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005;366:2026-2033.
21. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351: 1952-1961.
22. Siebenhofer A, Plank J, Horvath K, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: Meta-analysis of controlled double-blind randomized trials. Diabet Med. 2004;21:18-25.
23. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000;321:412-419.
24. Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxi-fylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract. 2005;99:73-77.
25. Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients - a randomized, equivalent trial. Clin Nephrol. 2005;64:91-97.
26. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. Am J Kidney Dis. 2008;52:454-463.
27. Harmankaya O, Seber S, Yilmaz M. Combination of pentoxi-fylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail. 2003;25:465-470.
28. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16: 2170-2179.
29. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540-1546.